Ready to Introduce the Medical Use of Cannabis in Italy
CBD is the medical abbreviation for cannabidiol, a metabolite of the more famous Cannabis, within which it is the substance present in the greatest proportion, after THC. Unlike the latter, however, CBD is not psychoactive, does not create addiction and has significant relaxing, anti-inflammatory, and pain-relieving properties. It is a compound with great pharmacological potential, but still little studied; an ancient remedy that we are rediscovering, but that, to date, is only available in an amateur and non-professional market.
Materia Medica Processing originates from a multidisciplinary team, with the aim of introducing into the Italian market a phytocomplex – that is, an integral extract of the hemp plant, devoid of any psychotropic action. A product that works by alleviating the symptoms of anxiety and stress, improving mood, and reducing any chronic and generalized inflammation; it is no coincidence that one of the most interesting areas of application is sports, since it is not considered a doping substance.
As Giovanni Isoldi explains in his interview, there is a large market, that in Italy stems from a regulatory gap, an emerging market that abroad is not overlooked, like in Canada, Israel, and the United States. And it is precisely in this context that Materia Medica Processing introduces its value proposition: a controlled product, highly traceable and with high quality standards, thanks to the most advanced technologies and a specific know-how on cannabinoid chemistry.
By joining TLS, Materia Medica Processing has been able to rely on a provider of infrastructures and services (a critical supporting figure for a startup); today, however, the Fondazione TLS is in all respects a trusted partner, with whom to share choices, strategies, and a vision of the future.
Materia Medica Processing has been incubated in TLS since 2018.

For more information: https://www.materiamedicaprocessing.eu/